Records Show Company Hid Data Pointing to Risperdal® Side Effects
September 2nd, 2015|
For years, studies have shown the use of the antipsychotic drug, Risperdal®, caused young teen boys to develop gynecomastia—a condition in which males grow excessive amounts of breast tissue. Now, allegations have arisen that the company that manufactured the drug, Janssen Pharmaceuticals, Inc., manipulated and hid data from the public indicating the increased risk of some Risperdal side effects.
Records show that both Janssen Pharmaceuticals, Inc., and their parent company, Johnson & Jonson, were aware of the risks the drug posed as early as 2003. Allegations released in an article from MedPage Today state the companies failed to publish or provide parts of a study to the U.S. Food and Drug Administration during the medication’s approval process that indicated male patients who take the drug may face an increased risk of gynecomastia. The study was just one of 44 examining the effects of Risperdal that were overseen by the companies.
These findings have prompted the results to be reinvestigated by an independent research team; however, officials say the conclusions drawn will have little effect on how Risperdal is distributed and prescribed in the United States.
This lack of action is why our drug injury lawyers at Fleschner, Stark, Tanoos & Newlin say it’s so important to be fully aware of the risks and all your legal rights before beginning a regimen of Risperdal medication. Knowing the effects the drug can have, as well as your freedoms as a patient, could help protect your health, safety, and security.